SPOTLIGHT: Abbott and Caprion Proteomics extend partnership

Abbott and Caprion Proteomics, a general partnership wholly owned by Thallion Pharmaceuticals have extended their discovery partnership to investigate viable human therapeutic antibody targets for oncology using their CellCarta technology platform. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.